AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and CV Outcomes in Patients with CKD
Patients with chronic kidney disease are at high risk of worsening kidney disease and cardiovascular events. Treatments that can slow down the worsening of kidney disease and reduce the need for dialysis and kidney transplants and the risk of cardiovascular events are potentially of great importance. While diabetes remains the biggest cause of chronic kidney disease, over half of patients with chronic kidney disease do not have diabetes, so treatments that work in people with and without diabetes are key.
In this interview, David Preiss MBChB, MRCP, FRCPath, PhD and Cindy L. Grines MD, FACC, MSCAI discuss AHA Late-Breaker: EMPA-KIDNEY – Empagliflozin and Cardiovascular Outcomes in Patients with CKD.
The AHA talk is the 2nd in a series of talks about the trial. The initial presentation about the trial will be at the American Society of Nephrology on 4th Dec, and my talk is on 6th Dec. I will focus mostly on results relevant to patients with cardiovascular disease, and will dedicate half the AHA presentation to a new meta-analysis.
- Empagliflozin in Patients with Chronic Kidney Disease; New England Journal of Medicine (to be published on 4th Nov 2022)
- IMPACT OF DIABETES ON THE RENAL EFFECTS OF SODIUM GLUCOSE CO-TRANSPORTER-2 (SGLT2) INHIBITORS: COLLABORATIVE METAANALYSIS OF LARGE PLACEBO-CONTROLLED TRIALS; Lancet (to be published on 6th Nov 2022)
Keywords: ACCELLite, Kidney
< Back to Listings